Recruiting

Century Therapeutics

Sponsor:

Century Therapeutics, Inc.

Code:

NCT05768269

Conditions

Hematological Malignancy

Solid Tumor Malignancy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

No Intervention

Study Details

Brief summary:

This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.

Conditions

Hematological Malignancy

Solid Tumor Malignancy

Study ID

NCT05768269

Start date

Apr 29, 2024

Status verified date

Jun, 2025

Completion date

Mar, 2040

Anticipated

Primary completion date

Mar, 2040

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
  • Participants received at least one treatment with a cellular therapy product in an eligible index trial.
  • Participant was withdrawn, early discontinued or completed an eligible index trial.
  • Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.

Exclusion Criteria:

-This study has no exclusion criteria.

Study Design

Enrollment

375 participants

Anticipated

Interventions and Outcome Measures

Arms

Cellular Therapy

Participants who have previously received an induced pluripotent stem cell (iPSC)-derived, ex vivo genome edited cellular therapy product in an eligible Century-sponsored index trial will be enrolled in this study for up to 180 months following the last treatment with a cellular therapy product in an eligible index trial.

Interventions

No Intervention

As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.

Primary outcome measure

  • Number of Participants With any Adverse Events of Special Interest (AESI) [ Time Frame: Up to 180 months ]

Central Contacts and Locations

Central contacts

Century Therapeutics Clinical Team

8885067670trial_response_century@centurytx.com

Locations

University of Maryland Medical Center

Recruiting

Baltimore, Maryland, United States, 21201

Contacts

Dr Nancy Hardy

410-328-1230nhardy1@umm.edu

Levine Cancer Institute

Recruiting

Charlotte, North Carolina, United States, 28204

Contacts

Dr Moyo

980-442-2301

University of Cincinnati Medical Center

Recruiting

Cincinnati, Ohio, United States, 45229

Contacts

Dr Latif

513-584-7824

Swedish Cancer Institute

Recruiting

Seattle, Washington, United States, 98104

Contacts

Dr. Krish Patel

206-991-2040krish.patel@swedish.org

More Information

Sponsor

Century Therapeutics, Inc.

Last update posted

Jun 25, 2025

Last verified

Jun, 2025

Keywords

  • Century Therapeutics
  • Cellular Therapy
  • Cell therapy
  • Malignancy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Century Therapeutics, Inc. on 2025-06-25.